AA-METOPROLOL SR TABLET (EXTENDED-RELEASE)

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

METOPROLOL TARTRATE

Tilgængelig fra:

AA PHARMA INC

ATC-kode:

C07AB02

INN (International Name):

METOPROLOL

Dosering:

200MG

Lægemiddelform:

TABLET (EXTENDED-RELEASE)

Sammensætning:

METOPROLOL TARTRATE 200MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100

Recept type:

Prescription

Terapeutisk område:

BETA-ADRENERGIC BLOCKING AGENTS

Produkt oversigt:

Active ingredient group (AIG) number: 0111923001; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2022-10-13

Produktets egenskaber

_AA-METOPROLOL SR (Metoprolol Tartrate Tablets) _
_ _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
AA-METOPROLOL SR
Metoprolol Tartrate Prolonged-release Tablets
Prolonged-release tablets, 100 mg and 200 mg, oral
House Standard
Beta-Adrenergic Receptor Blocking Agent
AA Pharma Inc.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Revision:
October 12, 2022
Submission Control Number: 262717
_AA-METOPROLOL SR (Metoprolol Tartrate Tablets) _
_ _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
Not applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
....................................................................................................................4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS.......................................................................................................5
4
DOSAGE AND ADMINISTRATION
.......................................................................................5
4.1
Dosing Considerations
................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................. 6
4.4
Administration............................................................................................................
8
4.5
Missed Dose
.